AlTorress

SRPT, Histogram just turned negative

Short
NASDAQ:SRPT   Sarepta Therapeutics, Inc.
This is a Bearish indicator signaling SRPT's price could decline from here. Traders may explore shorting the stock or put options. Tickeron's A.I. dvisor identified 44 similar cases where SRPT's MACD histogram became negative, and 35 of them led to successful outcomes. Odds of Success: 80%. Current price $170.73 is above $168.81 the highest support line found by Tickeron A.I. Throughout the month of 11/27/20 - 12/30/20, the price experienced a +23% Uptrend, while the week of 12/22/20 - 12/30/20 shows a -4% Downtrend.

Bearish Trend Analysis
The 10-day RSI Indicator for SRPT moved out of overbought territory on December 28, 2020. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 38 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Indicator may be shifting from an upward trend to a downward trend. In 46 of 68 cases where SRPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.

The Moving Average Convergence Divergence Histogram (MACD) for SRPT turned negative on December 30, 2020. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.